Cancers, Vol. 11, Pages 1570: Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer

Cancers, Vol. 11, Pages 1570: Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer Cancers doi: 10.3390/cancers11101570 Authors: Lum Alamgeer Small cell lung cancer (SCLC) accounts for approximately 10–15% of all lung cancers. The prognosis is poor with median survival in the advanced stage remaining at around 12 months. Despite applying every known therapeutic approach, no major breakthrough has improved the overall survival in the last 30 years. Historically, experiments performed on conventional cell lines may have limitations of not accurately reflecting the complex biological and genomic heterogeneity of this disease. However, additional knowledge gained from recently developed genetically engineered mouse models (GEMMs) and patient derived xenografts (PDXs) have made encouraging inroads. Whole genome sequencing (WGS) data reveals a high mutational burden and a number of genetic alterations but low frequency of targetable mutations. Despite several failures, considerable therapeutic opportunities have recently emerged. Potentially promising therapies include those targeting DNA damage repair, stem cell/renewal and drug resistant mechanisms. Modest success has also been achieved with immune checkpoint inhibitors while therapeutic exploration of various other components of the immune system is underway. However, the complex heterogeneities reflect the need for accurate bio-markers to translate novel discoveries into clinical benef...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

Conditions:   Carcinoma, Small Cell;   Solid Tumors;   SCLC;   Extrapulmonary Lung Cancer;   Relapse Interventions:   Drug: Topotecan + M6620;   Drug: Topotecan Sponsor:   National Cancer Institute (NCI) Recruiting
Source: - Category: Research Source Type: clinical trials
ConclusionThis study includes preliminary clinical data of SCLC patients with bone metastases at the time of diagnosis, and more studies are needed.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of lung cancer (LC) worldwide [1]. SCLC is a tumour that typically appears in heavy smokers, with 95% of SCLC patients being current or former smokers [2]. The incidence rate of SCLC has slightly decreased globally since the early 1990s, reflecting a general decrease in smoking habits [3]. The prognosis of SCLC is generally quite poor, with a median survival of 14-16 months for patients with Limited Disease (LD) and 8-11 months for those with Extensive Disease (ED).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Endobronchial Small-cell Lung Cancer with Intraluminal Growth Pattern Showing "Finger-in-glove" Appearance. Intern Med. 2019 Nov 08;: Authors: Kitahara Y, Murakami Y, Nakai S, Hiramatsu T, Kishimoto Y, Nihashi F, Aono Y, Eifuku T, Uto T, Sato J, Imokawa S, Suda T Abstract Invasion of the endobronchial mucosa by cancer cells is frequently seen in small cell lung cancer (SCLC), but an intraluminal polypoid growth pattern is extremely rare. We herein describe the case of a 69-year-old woman with limited-stage SCLC who had a pedunculated mass in the orifice of the right upper bronchus. Thin-secti...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Conclusion.DLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 may be targets for the treatment of SCLC.Implications for Practice.This article examines the relationship between delta‐like protein 3 (DLL3) and achaete‐scute homolog‐1 (ASCL1) protein expression with the clinical features of 95 surgically resected small cell lung cancer (SCLC). DLL3 is attracting attention because rovalpituzumab tesirine (Rova‐T), a DLL3‐targeted antibody‐drug conjugate, was developed recently. DLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer Source Type: research
Pulmonary high-grade neuroendocrine carcinoma includes the following two clinicopathological entities classified on the basis of their morphological and biological features: large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC) [1,2]. LCNEC and SCLC share several histological features, including rosette formation, molding of nuclei, and lack of apparent glandular formation and keratinization [3,4]. LCNEC, diagnosed in approximately 3% of all patients with lung cancer, is generally associated with high rate of metastases and poor patient survival [5,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study analyzed 352 patients enrolled in a previous randomized phase III trial comparing the efficacy of irinotecan plus cisplatin with that of etoposide plus cisplatin as the first ‐line therapy for ED‐SCLC. GNRI values were calculated using serum albumin levels and actual and ideal bodyweights. Patients with a GNRI >  98, 92–98, and
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Small cell lung cancer (SCLC) is a highly aggressive lung cancer subtype with poor survival and limited treatment options. Sequencing results have revealed gene mutations associated with SCLC, however, the cor...
Source: Respiratory Research - Category: Respiratory Medicine Authors: Tags: Research Source Type: research
Small cell lung cancer (SCLC) is an aggressive lung cancer subtype with extremely poor prognosis. No targetable genetic driver events have been identified, and the treatment landscape for this disease has remained nearly unchanged for over 30 years. Here, we have taken a CRISPR-based screening approach to identify genetic vulnerabilities in SCLC that may serve as potential therapeutic targets. We used a single-guide RNA (sgRNA) library targeting ~5000 genes deemed to encode "druggable" proteins to perform loss-of-function genetic screens in a panel of cell lines derived from autochthonous genetically engineered m...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement identifies a subgroup of patients who are sensitive to ALK tyrosine kinase inhibitors (TKIs) [1 –3]. Over the past years, a growing number of ALK rearrangement alterations has been identified in non-small cell lung cancer (NSCLC) predicting response to ALK TKIs treatment [4]. However, ALK fusion is extremely rare in small-cell lung cancer (SCLC). To the best of our knowledge, only two cases of SCLC harboring ALK fusion mutation has been reported previously, both of whom carrying EML4-ALK fusion [5,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Fine Needle Aspiration | Gastroschisis Repair | Genetics | Lung Cancer | Molecular Biology | Small Cell Lung Cancer | Stem Cell Therapy | Stem Cells | Ultrasound